The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | TRINITY: Rova-T for relapsed SCLC
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with multiple relapses have no approved treatment options. In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio State University, Athens, OH, describes the Phase II trial TRINITY (NCT02674568). This trial treated patients with two or more prior relapses with the DLL3 antibody-drug conjugate rovalpituzumab tesirine (Rova-T). The response rates were positive, and side effects from the treatment were manageable, suggesting that Rova-T could be a much sought after new treatment for relapsed SCLC.
